A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-06-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with
platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy in
PD-L1 negative, locally advanced or metastatic Non-small Cell Lung Cancer Patients. The
subjects were randomly divided into two groups according to 1:1, with about 325 subjects in
the experimental group and the control group.